VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets.
Company profile
Ticker
VTGN
Exchange
Website
CEO
Shawn K. Singh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Excaliber Enterprises, Ltd.
SEC CIK
Corporate docs
Subsidiaries
VistaStem Canada, Inc. • Artemis Neuroscience, Inc. ...
IRS number
205093315
VTGN stock data
Latest filings (excl ownership)
8-K
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3
23 Mar 23
EFFECT
Notice of effectiveness
22 Mar 23
S-3/A
Shelf registration (amended)
17 Mar 23
8-K
Other Events
8 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Mar 23
S-3
Shelf registration
2 Mar 23
8-K
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
1 Mar 23
D
$2.80 mm in equity, 129 investors
17 Feb 23
8-K
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
7 Feb 23
10-Q
2022 Q3
Quarterly report
7 Feb 23
Transcripts
VTGN
Earnings call transcript
2023 Q2
11 Nov 22
VTGN
Earnings call transcript
2023 Q1
12 Aug 22
VTGN
Earnings call transcript
2022 Q4
24 Jun 22
VTGN
Earnings call transcript
2022 Q3
11 Feb 22
VTGN
Earnings call transcript
2022 Q2
11 Nov 21
VTGN
Earnings call transcript
2022 Q1
12 Aug 21
VTGN
Earnings call transcript
2021 Q4
30 Jun 21
Latest ownership filings
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 23
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 23
SC 13G/A
ACUTA CAPITAL PARTNERS, LLC
14 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G/A
FRANKLIN RESOURCES INC
1 Feb 23
4
JERROLD DUANE DOTSON
3 Jan 23
4
Shawn Singh
3 Jan 23
4
JERRY B GIN
22 Aug 22
4
Reid G. Adler
19 Aug 22
4
Shawn Singh
18 Aug 22
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 25.04 mm | 25.04 mm | 25.04 mm | 25.04 mm | 25.04 mm | 25.04 mm |
| Cash burn (monthly) | 3.42 mm | 4.89 mm | 3.26 mm | 5.31 mm | 3.31 mm | 4.82 mm |
| Cash used (since last report) | 9.91 mm | 14.18 mm | 9.44 mm | 15.40 mm | 9.60 mm | 13.98 mm |
| Cash remaining | 15.13 mm | 10.86 mm | 15.60 mm | 9.64 mm | 15.44 mm | 11.06 mm |
| Runway (months of cash) | 4.4 | 2.2 | 4.8 | 1.8 | 4.7 | 2.3 |
Institutional ownership, Q4 2022
45.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 90 |
| Opened positions | 11 |
| Closed positions | 17 |
| Increased positions | 22 |
| Reduced positions | 27 |
| 13F shares | Current |
|---|---|
| Total value | 3.29 bn |
| Total shares | 87.83 mm |
| Total puts | 5.10 k |
| Total calls | 13.80 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Venrock Healthcare Capital Partners II | 20.70 mm | $26.49 mm |
| Growth Equity Opportunities 17 | 16.30 mm | $35.05 mm |
| BLK Blackrock | 12.27 mm | $1.26 bn |
| STT State Street | 6.16 mm | $634.77 mm |
| Rosalind Advisors | 5.38 mm | $10.43 mm |
| Gsa Capital Partners | 5.10 mm | $525.00 k |
| Vanguard | 4.73 mm | $487.60 mm |
| Lincoln Park Capital Fund | 4.61 mm | $3.68 mm |
| Geode Capital Management | 3.27 mm | $337.00 k |
| NTRS Northern Trust | 1.75 mm | $179.96 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Dec 22 | Dotson Jerrold Duane | Common Stock | Grant | Acquire A | No | No | 0.0876 | 5,000 | 438.00 | 105,111 |
| 30 Dec 22 | Singh Shawn | Common Stock | Grant | Acquire A | No | No | 0.0876 | 5,000 | 438.00 | 158,998 |
| 18 Aug 22 | Gin Jerry B | Common Stock | Buy | Acquire P | Yes | No | 0.1787 | 100,000 | 17.87 k | 100,000 |
| 18 Aug 22 | Gin Jerry B | Common Stock | Buy | Acquire P | No | No | 0.1787 | 100,000 | 17.87 k | 100,000 |
| 17 Aug 22 | Singh Shawn | Common Stock | Buy | Acquire P | Yes | No | 0.172 | 600,000 | 103.20 k | 626,234 |
| 17 Aug 22 | Reid G. Adler | Common Stock | Buy | Acquire P | No | No | 0.1697 | 300,000 | 50.91 k | 334,629 |
News
Why VistaGen Therapeutics Shares Are Trading Higher Today
22 Mar 23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
22 Mar 23
Vistagen Announces Data From Phase 3 Open-Label Study To Evaluate Safety And Tolerability Of PH94B; Was Safe And Well Tolerated
22 Mar 23
Vistagen Announces Completion Of Last Patient, Last Visit In Phase 1 Clinical Trial Of Itruvone, An Investigational Pherine Nasal Spray For Major Depressive Disorder; Top Line Results Anticipated In Q2 2023
8 Mar 23
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
13 Feb 23
Press releases
Thinking about buying stock in Vistagen Therapeutics, NVIDIA, SoFi Technologies, Carnival Corp, or Nike?
22 Mar 23
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
22 Mar 23
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
8 Mar 23
Vistagen to Present at Cowen 43rd Annual Health Care Conference
2 Mar 23
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
1 Mar 23